Research performed in the laboratories of Professors Francois Berthiaume and Martin Yarmush in collaboration with researchers at Araim Pharmaceuticals was recently published in the Proceedings of the National Academy of Sciences. The collaborative study showed that systemic administration of ARA290 (a peptide from the protein erythropoietin) after burn injury is highly effective in reducing burn wound expansion by preventing microvascular thrombosis and progressive tissue necrosis. Thus ARA290 may be a promising therapeutic approach to prevent the conversion of partial- to full-thickness burn injuries. The full paper describing this work can be found in PNAS Early View, February 11, 2013.